Mostrando postagens com marcador Ebola outbreak. Mostrar todas as postagens
Mostrando postagens com marcador Ebola outbreak. Mostrar todas as postagens

terça-feira, 11 de novembro de 2014

Take action to help #EndEbola

 

 

Snap 2014-11-11 at 17.03.42

 

The Ebola outbreak in West Africa has claimed more than 4,500 lives, and the number of cases grows every day. Our window to stop the Ebola outbreak from spiraling further out of control is closing fast – action is needed now.

The United Nations has a roadmap to stop the spread of Ebola. If G20 countries can commit and deploy the money, troops, and medics needed by the time they meet on November 15, we’ll be on track to start seeing the number of new cases decline by December.

Add your name below and tell the G20 countries: Step up your commitments and help #EndEbola, before it's too late.

Petition

What’s needed NOW to save lives: More money. More troops. More medics.

To G20 country leaders:

With the deadly Ebola virus continuing to tear through West Africa, we urge you to swiftly ensure all the personnel, equipment and funding required to halt the outbreak are made available, as outlined by the Framework for a Global Response to the Ebola Outbreak. By the time the G20 meets in Australia on November 15-16th, the world must be firmly on track to defeat the virus.

We have a window of a few weeks to contain this epidemic. Please act immediately to prevent this epidemic from causing further suffering and devastating more lives across West Africa, and beyond. We call on all G20 members to show real commitment and leadership in the midst of this global crisis and act now.

quinta-feira, 23 de outubro de 2014

Ebola Vaccines May Be Deployed in West Africa by January, Officials Say

 

TUESDAY Oct. 21, 2014, 2014 -- A pair of promising Ebola vaccines could be deployed against the outbreak ravaging three West African nations by January, experts say.

Rival American and Canadian vaccines are being prepared for possible use in Guinea, Liberia and Sierra Leone, but first they have to pass expedited human safety trials in the United States, manufacturers say.

If all goes well, inoculation of frontline health workers in West Africa could begin in early 2015.

On Tuesday, a top official from the World Health Organization (WHO) said it's possible that tens of thousands of doses could be available for "real-world" testing in West Africa by January, the Associated Press reported.

Dr. Marie Paule Kieny, an assistant director general for WHO, said preliminary safety data on both vaccines should be available by December.

Twenty human subjects have already been injected with the American vaccine in one of the safety trials, and by the end of November or early December researchers will know whether it is safe, said Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The agency is developing this vaccine with drug maker GlaxoSmithKline.

"I don't know if that's going to be the best one, but that's the one farthest along in terms of development," Fauci said.

At the same time, Canada has started shipping its own experimental vaccine to WHO, sending 800 vials for possible use in West Africa.

Those vials are expected to arrive in Switzerland on Wednesday for testing among volunteers in Geneva, Hamburg, Germany, and the African nations of Gabon and Kenya, according to the AP.

"These data are absolutely crucial to allow decision-making on what dose level should go in the efficacy testing in Africa," Kieny said. "We expect, we hope, to have a go-ahead by the end of the month."

That would allow the vaccine to be shipped for use in West Africa immediately afterward.

The Canadian vaccine is being produced by the Public Health Agency of Canada and NewLink Genetics, a U.S. firm that holds the license for the vaccine.

The Canadian vaccine has also entered the human testing stage in the United States, with about 40 volunteers at the Walter Reed Army Institute of Research in Maryland receiving a dose, according to Canadian Health Minister Rona Ambrose.

The American and Canadian vaccines appear to be the most promising, in that they are far enough along that they might be put into use during the current Ebola epidemic, said Dr. Craig Smith, medical director of infectious diseases at University Health Care System in Augusta, Ga.

"Both of these vaccines are the top choices for availability and production," Smith said. "They're not ready for prime time if it wasn't an emergency situation, but they are the ones the World Health Organization is supporting."

The two vaccines both aim to create immunity to Ebola through the use of a simpler, less harmful virus into which Ebola genetics have been spliced, Smith said.

The American vaccine uses a chimpanzee cold virus, called chimp adenovirus type 3, to deliver Ebola genetic material to human cells. The Canadian vaccine uses a virus common to cattle and horses called vesicular stomatitis virus (VSV), which is in the same viral family as the rabies virus but causes only flu-like symptoms in infected humans.

The goal of both vaccines is to trigger an immune system response that creates antibodies that will defend the body against Ebola infection. Both have shown promise in animal trials.

There are several other Ebola vaccines in development. Researchers at Thomas Jefferson University in Philadelphia have developed an Ebola vaccine that piggybacks on the established rabies virus vaccine, for example.

But the other vaccines are not likely to be ready in time for this epidemic. "It's not that they aren't good, it's just that they aren't farther along in development," Fauci explained.

It's an open question whether any of these vaccines will be available in time and in large enough quantities to do any good.

Alan Barrett, director of the Sealy Center for Vaccine Development at the University of Texas Medical Branch, said that even with a revved-up testing schedule, "having a vaccine that would have an effect on this epidemic is unlikely. It's just not going to be ready in time."

But if the epidemic is still raging into early 2015 and the vaccines prove safe, Barrett said health care workers likely will be the first people in West Africa to receive inoculations.

"Clearly, you want your health care workers immunized, because otherwise they can't help those who are ill," he said.

Which people next receive the vaccine will be a matter of both scientific and ethical debate, Barrett said. The vaccine must be used in a way that can prove its clinical effectiveness, but with thousands dying it may be difficult to stick to such standards.

WHO likely will use a technique called "cluster randomization" to test the effectiveness of Ebola vaccines, Smith said.

"As the vaccine becomes available, you vaccinate everyone in one village, and then compare their progress to that of other unvaccinated villages," he said. "That way, you're not using placebo. If you go in to vaccinate a village, they know that they are all going to get the vaccine."

Smith said this type of clinical trial is not commonly used "because placebo control studies are the gold standard," but it would likely need to be used in the face of a deadly epidemic.

More than 4,500 people have already died from the Ebola virus, and public health experts have said there could be 10,000 new cases a week by the end of the year if stronger measures to fight the often deadly virus are not taken.

More information

Visit the U.S. Centers for Disease Control and Prevention for more on the Ebola virus.

Snap 2014-10-23 at 12.26.46

quarta-feira, 22 de outubro de 2014

How Did Nigeria Quash Its Ebola Outbreak So Quickly?

 

What we can learn from the boot leather, organization and quick response times that stopped Ebola from spreading in this African nation

ebola in Nigeria

Empty ebola ward in Nigeria. Credit: CDC Global via flickr

On July 20 a man who was ill flew on commercial planes from the heart of the Ebola epidemic in Liberia to Lagos, Nigeria's largest city. That man became Nigeria's first Ebola case—the index patient. In a matter of weeks some 19 people across two states were diagnosed with the disease (with one additional person presumed to have contracted it before dying).

But rather than descending into epidemic, there has not been a new case of the virus since September 5. And since September 24 the country's Ebola isolation and treatment wards have sat empty. If by Monday, October 20 there are still no new cases, Nigeria, unlike the U.S., will be declared Ebola free by the World Health Organization (WHO).

What can we learn from this African country's success quashing an Ebola outbreak?

Authors of a paper published October 9 in Eurosurveillance attribute Nigeria's success in "avoiding a far worse scenario" to its "quick and forceful" response. The authors point to three key elements in the country's attack:

  • Fast and thorough tracing of all potential contacts
  • Ongoing monitoring of all of these contacts
  • Rapid isolation of potentially infectious contacts

The swift battle was won not only with vigilant disinfecting, port-of-entry screening and rapid isolation but also with boot leather and lots and lots of in-person follow-up visits, completing 18,500 of them to find any new cases of Ebola among a total of 989 identified contacts.

Such ground-level work may sound extreme, and the usually measured WHO declared the feat "a piece of world-class epidemiological detective work." But as William Schaffner, chair of the Department of Preventive Medicine and an infectious disease expert at Vanderbilt University, says, "Actually what Nigeria did is routine, regular—but vigorous and rigorous—public health practice. They identified cases early—fortunately they had a limited number—and they got a list of all of the contacts, and they put those people under rigorous surveillance so that if they were to become sick, they wouldn't transmit the infection to others," he says.

Art Reingold, head of epidemiology at the University of California, Berkeley, School of Public Health agrees. The steps are basic: "isolation, quarantine of contacts, etcetera," but governments must "get in quickly and do it really well." It was Nigeria's vigorous and rapid public health response that really stopped the spread. Because when Ebola lands one August afternoon in a city of 21 million, things could go very, very differently.

Race to prevent spread
Nigeria's index patient had been caring for a family member in Liberia who died from Ebola on July 8. Despite having been hospitalized in the Liberian capital Monrovia with fever and Ebola symptoms on July 17, he left medical care (against advice) and three days later took a commercial flight to Nigeria via Togo. After landing he collapsed at the Lagos airport and was taken to the hospital.

There it took three days before an Ebola diagnosis was made. The patient said he had no known exposure to Ebola, so he was first thought to have malaria, which is common and can have similar symptoms including fever, vomiting and headache. After malaria treatment failed to improve the patient's symptoms, however, medical staff began to consider Ebola, especially given his recent travel history. He was moved to isolation while test results confirmed the virus.

From this single individual, who died from the disease July 25, infectious disease experts generated a list of 898 contacts. Why so many? In addition to having become ill in a public place, the patient also infected an individual who then flew to and back from another Nigerian city, Port Harcourt, in late July while sick. That individual passed the infection to three other people, including a health care worker who died on August 22—but not before generating 526 more contacts. The index patient's primary and secondary contacts had only added up to 351.

The fact that two individuals were able to generate so many contacts shows just how vigilant authorities must be in tracking every last potential exposure. But the vigilance paid off. No new cases have been diagnosed in more than a month, and October 1 marked the date at which all of Nigeria’s 898 contacts passed the 21-day incubation period during which Ebola symptoms can present themselves.

The epidemic that wasn't
The arrival location of the index patient was a prime place to cause a widespread outbreak. Lagos is Africa's largest city, with a population of 21 million. It is a major hub for travel and business. "A dense population and overburdened infrastructure create an environment where diseases can be easily transmitted and transmission sustained," wrote the authors of
a paper for the U.S. Centers for Disease Control and Prevention's (CDC) Morbidity and Mortality Weekly Report (MMWR). As such, "A rapid response using all available public health assets was the highest priority."

But, says Folorunso Oludayo Fasina, a senior lecturer at the University of Pretoria in South Africa, co-author of the Eurosurveillance paper and a native Nigerian, it was actually lucky that the index patient in Nigeria fell ill at the airport. "Had the index case gotten the opportunity to contact persons in Lagos or Calabar—[another Nigerian city] where he was to deliver a lecture—it may have been a complete disaster."

Although it took three days to diagnose Ebola (a period during which nine health care workers were infected with the disease), once the diagnosis was confirmed health authorities swung into action. The Federal Ministry of Health worked with the CDC’s Nigerian office to declare an Ebola emergency. On July 23—the very same day the patient was diagnosed—they created an Incident Management Center (which morphed into the Emergency Operations Center) and kicked into action an Incident Management System to coordinate responses. Such a centralized and coordinated system "is largely credited with helping contain the Nigerian outbreak early," the MMWR authors wrote.

It wasn't the Emergency Operations Center's first time tackling a highly infectious disease. Two years ago, after a global call from WHO, Nigeria redoubled its efforts to eradicate polio, another infectious virus, within its borders. The center has played a large role in working toward that goal, improving response times and preparedness along the way, the authors of the MMWR paper wrote. Many of those leading the Ebola response were chosen for their success working on polio eradication.

The government's first priority was to locate all potential contacts. A team of more than 150 designated "contact tracers" tracked down each of the individuals. Such tracing is the most challenging part of this sort of work, Fasina says, especially in Nigeria, where "houses cannot always be traced by street numbers." With all of those potentially exposed to the virus pinpointed, workers conducted an astounding 18,500 face-to-face visits to check for fever and other Ebola-related symptoms in each of these contacts, according to data in the MMWR paper. The check-ups took a little cajoling, Fasina notes. To get folks to meet with tracers also requires a good deal of effort to remove social stigma around the disease.

Any individual showing symptoms was quickly moved to an isolation ward for further testing, which could be completed locally at the Lagos University Teaching Hospital for rapid diagnosis. Once an Ebola case was confirmed, patients were transferred to a special Ebola virus treatment center. Even those contacts that tested negative but showed Ebola-like symptoms were held—separately from Ebola patients—until all symptoms resolved. As cases were confirmed the Emergency Operations Center tracked down additional contacts and decontaminated potentially infectious areas.

In addition to contact tracing and rapid isolation, teams of "social mobilizers" canvassed areas around the homes of Ebola contacts, reaching around an additional 26,000 households with health information. Communicating that information effectively to the broader public is another challenge. Ensuring that people have confidence in the government—and understanding of what it is trying to do—is absolutely key, Vanderbilt’s Schaffner notes. Part of that is controlling what he calls "the outbreak of anxiety."

Lessons for the U.S.
The U.S. outbreak so far has many similarities to the one in Nigeria but "countries such as the U.S. have some lessons to learn," Fasina says. "Infectious disease is the same everywhere but the management may differ," leading to vastly different outcomes.

Schaffner agrees that the U.S. response has not been perfect. "There isn't any doubt that we've stumbled both on the clinical side, with misdiagnoses and insufficient training and supervision in the hospital, and on the public health side," allowing and infected nurse to fly commercially while she was under surveillance, he says. "Now that we've stumbled we shouldn't do it again."

U.S. government agencies seem to be learning. The CDC has beefed up its safety protocols for health care workers dealing with infectious patients and contact monitoring is exercised more strenuously. WHO, for example, recommends that even health care workers and cleaning staff who have used personal protective equipment and followed all the safety rules when dealing with an Ebola patient be considered "close contacts" and monitored for 21 days. This stands in contrast to the untrained health care workers in Dallas who treated the U.S. index patient (in what likely turned out to be less-than-optimal protective equipment) and were initially asked simply to self-monitor.

The key takeaways are: coordinate, track and monitor. "The Nigerian experience offers a critically important lesson to countries in the region not yet affected by the [Ebola] epidemic as well as to countries in other regions of the world," the Eurosurveillance authors noted. "No country is immune to the risk…[but] rapid case identification and forceful interventions can stop transmission."

Global battle
Public health experts agree that the best way to reduce risk of an outbreak in other countries is to stop the epidemic in west Africa. According to
the latest statistics from WHO, as of October 17 some 9,216 people have contracted the illness and at least 4,555 have died. The bulk of the cases have occurred in Guinea, where the epidemic originated, Liberia and Sierra Leone. What was so different in Nigeria compared with neighboring countries farther west?

As the authors of the Eurosurveillance note, the rapid action after Nigeria's index patient was diagnosed helped keep the outbreak from spreading more widely. "In contrast the initial outbreak in Guinea remained undetected for several weeks," they wrote. "This detection delay facilitated the transnational spread of the virus to Sierra Leone and Liberia while difficulties and at times inability to track and contain infectious individuals compounded the situation and resulted in an as yet uncontrolled epidemic in these countries."

Now there are just too many people who are ill—or have had contact with the virus—to track in those nations, Schaffner says. And Sierra Leone's announcement on October 10 that it would provide rudimentary kits for people to care for sick family members at home makes the situation that much more dire. To be sure, it will keep sick people from traveling to health centers that are at overcapacity only to get turned away, possibly infecting others along the way. But, Schaffner notes, the "core public health reason for taking that individual out of that family is that you interrupt transmission." Until additional care facilities are prepared to take in the surge of patients the outbreak will continue to spread untracked and untraced.

The difference between a stemmed outbreak and a full epidemic often also comes down to a question of resources and how quickly they can be made available. "In the three badly affected countries," Reingold says, "dreadful preexisting infrastructure and inadequate resources and capabilities" due in part to poverty, civil war and corruption have made executing standard public health practices for outbreak control nearly impossible. And time is of the essence: "To deal with the out-of-control outbreak there will take immense infrastructure building, staffing, resources and money," Reingold says. "The longer it takes for them to arrive—or to be put in place—the more difficult the job."

In Nigeria the response team was able to corral enough funding, staff and tools from state partners, international groups and nongovernmental organizations to successfully launch its attack on the outbreak right away. "National preparedness efforts should consider how resources can be quickly accessible to fund the early stage of the response," the authors of the MMWR paper wrote.

"Every country needs to evaluate its preparedness and must be ready to respond to [an] emergency immediately," Fasina says. "Nigeria was not completely ready," but they identified the index case early and then hit the streets.

Snap 2014-09-13 at 12.29.02

segunda-feira, 13 de outubro de 2014

Fast, simple diagnostic test specific to 2014 Ebola outbreak

 


Primerdesign kit.

High-tech British company Primerdesign Ltd, a spin-off company from the University of Southampton, has developed a fast and simple diagnostic test solution specific to the 2014 Ebola outbreak.

With the current epidemic of Ebola virus in West Africa, Primerdesign are racing to provide an easy-to-use, affordable solution for screening suspect Ebola patients.

"Accurate diagnostics is essential in controlling an outbreak like Ebola. There is an urgent need for rapid testing to screen suspected patients and people travelling in and out of the region," explains Dr Jim Wicks, Managing Director of Primerdesign. "Our test is quick, affordable and easy to perform," he adds.

The kit detects the DNA finger print of the Ebola Virus. It means that even minute quantities of the disease can be detected in the early stages allowing for pre-emptive healthcare intervention.

Primerdesign Ltd, which is part of the university business incubator collaboration SETsquared, has finished development work in the last few days and is meeting with the World Health Organisation to discuss plans to possibly put large numbers of these tests in to the front line in West Africa as quickly as possible.

How the kit works

Viruses all have a unique genetic fingerprint the same as we do. Ours is encoded in DNA but the Ebola virus uses RNA (Ribonucleic acid). So the kit is designed to specifically detect the Ebola RNA in a patient blood sample.

Process:

  1. Blood sample is taken from patient
  2. RNA is extracted with a few simple steps
  3. RNA is placed in a tube with our kit ingredients
  4. Tube goes in to machine
  5. Analysis complete within 90 minutes

Primerdesign is a spinoff company from the University of Southampton specialising in Real-Time PCR technology. Real-Time PCR, also known as 'qPCR' is a mature technology based on the same DNA testing technology of 'CSI' fame. Primerdesign deployed the same technology during the recent horsemeat scandal in the UK and famously developed the World's first Swine Flu detection kit in the 2009 outbreak.


Story Source:

The above story is based on materials provided by University of Southampton. Note: Materials may be edited for content and length.


 

sábado, 20 de setembro de 2014

Possible 6,800 new Ebola cases this month, research predicts

 


New research published today in the online journal PLoS Outbreaks predicts new Ebola cases could reach 6,800 in West Africa by the end of the month if new control measures are not enacted.

Arizona State University and Harvard University researchers also discovered through modelling analysis that the rate of rise in cases significantly increased in August in Liberia and Guinea, around the time that a mass quarantine was put in place, indicating that the mass quarantine efforts may have made the outbreak worse than it would have been otherwise. Deteriorating living and hygiene conditions in some of the quarantined areas sparked riots last month. Sierra Leone began a three day country-wide quarantine today, where all citizens have been asked to stay at home, said Sherry Towers, research professor for the ASU Simon A. Levin Mathematical, Computational and Modelling Sciences Center (MCMSC).

"There may be other reasons for the worsening of the outbreak spread, including the possibility that the virus has become more transmissible, but it's also possible that the quarantine control efforts actually made the outbreak spread more quickly by crowding people together in unsanitary conditions," Towers said.

The study, "Temporal variations in the effective reproduction number of the 2014 West Africa Ebola outbreak," is authored by Towers, Oscar Patterson-Lomba of the Harvard School of Public Health and Carlos Castillo-Chavez, ASU Regent's professor and MCMSC executive director.

Researchers assessed whether or not attempted control efforts are effective in curbing the ongoing West African Ebola outbreak that has spread over a large geographic area, causing thousands of infections and deaths. Because the outbreak has spread to densely populated areas, the risk of international spread is increased. Also compounding the problem is a lack of resources for effective quarantine and isolation in the under-developed countries that have been affected, and the high mobility of the population in a region with porous borders, according to the study.

"No licensed vaccine or specific treatment for the disease is currently available. This leaves improved hygiene, quarantine, isolation and social distancing as the only potential interventions," Castillo-Chavez said. "Improved control measures must be put into place." On Tuesday, President Obama announced that 3,000 US troops and medical personnel would be sent to the region to help control the outbreak, he added.

Researchers examined the current outbreak data for Guinea, Sierra Leone and Liberia through statistical research methods up until Sept. 8, 2014, as estimated by the World Health Organization. The analysis examines the local rates of exponential rise to estimate how the reproduction number of cases appears to be changing over time. Calculations showed a range of 6,800 predicted new cases at the upper end of the spectrum and 4,400 on average. The study was funded by the National Institute of General Medical Sciences at the National Institutes of Health.

Further information can be found at: http://currents.plos.org/outbreaks/article/temporal-variations-in-the-effective-reproduction-number-of-the-2014-west-africa-ebola-outbreak/


Story Source:

The above story is based on materials provided by Arizona State University. Note: Materials may be edited for content and length.

quarta-feira, 17 de setembro de 2014

Ebola outbreak 'out of all proportion' and severity cannot be predicted, expert says


This image was captured in Monrovia, Liberia’s capital city, during the 2014 West African Ebola hemorrhagic fever (Ebola HF) outbreak that affected not only Liberia, but Sierra Leone, Guinea, and Nigeria as well.

A mathematical model that replicates Ebola outbreaks can no longer be used to ascertain the eventual scale of the current epidemic, finds research conducted by the University of Warwick.

Dr Thomas House, of the University’s Warwick Mathematics Institute, developed a model that incorporated data from past outbreaks that successfully replicated their eventual scale.

The research, titled "Epidemiological Dynamics of Ebola Outbreaks" and published by eLife, shows that when applying the available data from the ongoing 2014 outbreak to the model that it is, according to Dr House, “out of all proportion and on an unprecedented scale when compared to previous outbreaks”.

Dr House commented: “If we analyse the data from past outbreaks we are able to design a model that works for the recorded cases of the virus spreading and can successfully replicate their eventual size. The current outbreak does not fit this previous pattern and, as a result, we are not in a position to provide an accurate prediction of the current outbreak”.   

Chance events, Dr House argues, are an essential factor in the spread of Ebola and many other contagious diseases. “If we look at past Ebola outbreaks there is an identifiable way of predicting their overall size based on modelling chance events that are known to be important when the numbers of cases of infection are small and the spread is close to being controlled”.

Chance events can include a person’s location when they are most infectious, whether they are alone when ill, the travel patterns of those with whom they come into contact or whether they are close to adequate medical assistance.

The Warwick model successfully replicated the eventual scale of past outbreaks by analysing two key chance events: the initial number of people and the level of infectiousness once an epidemic is underway.

“With the current situation we are seeing something that defies this previous pattern of outbreak severity. As the current outbreak becomes  more severe, it is less and less likely that it is a chance event and more likely that something more fundamental has changed”, says Dr House.

Discussing possible causes for the unprecedented nature of the current outbreak, Dr House argues that there could be a range of factors that lead it to be on a different scale to previous cases; “This could be as a result of a number of different factors: mutation of virus, changes in social contact patterns or some combination of these with other factors. It is implausible to explain the current situation solely through a particularly severe outbreak within the previously observed pattern”.

In light of the research findings and the United Nations calling for a further $1bn USD to tackle the current outbreak, Dr House says that “Since we are not in a position to quantify the eventful scale of this unprecedented outbreak, the conclusion from this study is not to be complacent but to mobilise resources to combat the disease.”

Snap 2014-09-12 at 18.10.27


Story Source:

The above story is based on materials provided by University of Warwick. Note: Materials may be edited for content and length.


Journal Reference:

  1. Thomas House. Epidemiological Dynamics of Ebola Outbreaks. eLife, 2014; 3 DOI: 10.7554/eLife.03908

segunda-feira, 15 de setembro de 2014

Protein secrets of Ebola virus

 


The current Ebola virus outbreak in West Africa, which has claimed more than 2000 lives, has highlighted the need for a deeper understanding of the molecular biology of the virus that could be critical in the development of vaccines or antiviral drugs to treat or prevent Ebola hemorrhagic fever.

The current Ebola virus outbreak in West Africa, which has claimed more than 2000 lives, has highlighted the need for a deeper understanding of the molecular biology of the virus that could be critical in the development of vaccines or antiviral drugs to treat or prevent Ebola hemorrhagic fever. Now, a team at the University of Virginia (UVA), USA -- under the leadership of Dr Dan Engel, a virologist, and Dr Zygmunt Derewenda, a structural biologist -- has obtained the crystal structure of a key protein involved in Ebola virus replication, the C-terminal domain of the Zaire Ebola virus nucleoprotein (NP).

The team explains that their structure reveals a novel tertiary fold that is expected to lead to insights into how the viral nucleocapsid is assembled in infected cells. The structure could also provide a basis for the design of drugs to halt infection in humans. "The structure is unique in the RNA virus world," Derewenda explains. "It is not found in viruses that cause influenza, rabies or other diseases." It distantly resembles the β-grasp protein motif found in ubiquitin, most likely the result of convergent evolution.

Like many other related viruses, Ebola virus contains a negative-sense, single-stranded RNA that encodes seven different proteins, one of which is known as the nucleoprotein (NP) for its ability to interact with the viral RNA genome. It is the most abundant viral protein found in infected cells and also inside the viral nucleocapsid. While five of the seven viral proteins have succumbed to structural characterization by X-ray crystallography, NP so far has resisted such attempts, although analogous proteins from other viruses have had their structures analysed.

The UVA team produced the Ebola protein using an engineered form of Escherichia coli bacteria as a protein factory. This allowed them to identify the boundaries of two globular domains and to crystallize the unique C-terminal domain spanning amino-acid residues 641 to 739. The study revealed a molecular architecture unseen so far among known proteins, the team says. There is existing evidence that the newly characterized domain is involved in transcription and the self-assembly of the viral nucleocapsid. As such, the results obtained by the UVA team will be useful in deciphering precisely how these various functions are accomplished by the virus; such a detailed description offers up a potential target for the design of anti-viral drugs.

Snap 2014-09-12 at 18.10.27


Story Source:

The above story is based on materials provided by International Union of Crystallography. Note: Materials may be edited for content and length.


Journal Reference:

  1. Paulina J. Dziubańska, Urszula Derewenda, Jeffrey F. Ellena, Daniel A. Engel, Zygmunt S. Derewenda. The structure of the C-terminal domain of theZaire ebolavirusnucleoprotein. Acta Crystallographica Section D Biological Crystallography, 2014; 70 (9): 2420 DOI: 10.1107/S1399004714014710

sábado, 13 de setembro de 2014

Experts call for massive global response to tackle Ebola

 


The current Ebola outbreak now requires a 'rapid response at a massive global scale,' according to experts. Writing an editorial in Science, Professor Peter Piot, co-discoverer of the virus, says that the epidemic in West Africa is the result of a "perfect storm" involving dysfunctional health services, low trust in governments and Western medicine, denials about the virus's existence, and unhygienic burial practices.

The outbreak which began in December 2013 now spans five countries in West Africa and has so far killed nearly 2000 people, with the WHO predicting that 20,000 may become infected.

Professor Piot, Director of the London School of Hygiene & Tropical Medicine, writes: "This fast pace of Ebola's spread is a grim reminder that epidemics are a global threat and that the only way to get this virus under control is through a rapid response at a massive global scale -- much stronger than the current efforts."

According to Professor Piot, international assistance to the growing local efforts must include support for disease-control activities such as the provision of protective equipment, patient care, and addressing the health, nutritional, and other needs of populations in quarantine.

It is also an opportune time to accelerate evaluation of experimental therapies and vaccines. With the WHO announcing that compassionate use of experimental therapies is ethically justified, even if they have not been tested in humans, Professor Piot comments that "an exceptional crisis requires an exceptional response."

In a separate article in Eurosurveillance, Professor Piot and colleague Dr Adam Kucharski delve deeper into the challenges currently facing West Africa. They warn that the exponential growth in numbers makes tracing and surveillance for Ebola increasingly difficult, and that cases could double every fortnight if the situation remains the same.

Professor Piot and Dr Kucharski write: "Fear and mistrust of health authorities has contributed to this problem, but increasingly it is also because isolation centres have reached capacity. As well as creating potential for further transmission, large numbers of untreated -- and therefore unreported -- cases make it difficult to measure the true spread of infection, and hence to plan and allocate resources."

They also warn that it is not just Ebola patients who are affected by the outbreak. In cities like Monrovia in Liberia, the infection has led to the closure of most health facilities, and as a result, untreated injuries and illnesses have caused further loss of life.


Story Source:

The above story is based on materials provided by London School of Hygiene & Tropical Medicine. Note: Materials may be edited for content and length.


Journal References:

  1. P. Piot. Ebola's perfect storm. Science, 2014; 345 (6202): 1221 DOI: 10.1126/science.1260695
  2. A J Kucharski, P Piot. Containing Ebola virus infection in West Africa. Eurosurveillance, Volume 19, Issue 36, 11 September 2014 [link]

sábado, 30 de agosto de 2014

WHO issues roadmap to scale up international response to the Ebola outbreak in west Africa

 


The World Health Organization (WHO) has issued a roadmap to guide and coordinate the international response to the outbreak of Ebola virus disease in west Africa.

The aim is to stop ongoing Ebola transmission worldwide within 6-9 months, while rapidly managing the consequences of any further international spread. It also recognizes the need to address, in parallel, the outbreak's broader socioeconomic impact.

It responds to the urgent need to dramatically scale up the international response. Nearly 40% of the total number of reported cases have occurred within the past three weeks.

The roadmap was informed by comments received from a large number of partners, including health officials in the affected countries, the African Union, development banks, other UN agencies, Médecins Sans Frontières (MSF), and countries providing direct financial support.

It will serve as a framework for updating detailed operational plans. Priority is being given to needs for treatment and management centres, social mobilization, and safe burials. These plans will be based on site-specific data that are being set out in regular situation reports, which will begin this week.

The situation reports map the hotspots and hot zones, present epidemiological data showing how the outbreak is evolving over time, and communicate what is known about the location of treatment facilities and laboratories, together with data needed to support other elements of the roadmap.

The roadmap covers the health dimensions of the international response. These dimensions include key potential bottlenecks requiring international coordination, such as the supply of personal protective equipment, disinfectants, and body bags.

The WHO roadmap will be complemented by the development of a separate UN-wide operational platform that brings in the skills and capacities of other agencies, including assets in the areas of logistics and transportation. The UN-wide platform aims to facilitate the delivery of essential services, such as food and other provisions, water supply and sanitation, and primary health care.

Resource flows to implement the roadmap will be tracked separately, with support from the World Bank.


Story Source:

The above story is based on materials provided by World Health Organization. Note: Materials may be edited for content and length.